Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

U.S. stocks climbed Monday as investors cheered President-elect Donald Trump’s choice for Treasury secretary ahead of a ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $26.48 which represents a decrease of $-5.70 or -17.71% from the prior close of $32.18. The stock opened at $31.36 and ...

Cassava Sciences ( SAVA) stock dropped 87% on Monday to close the day’s trading at $4.29 a shares. Cassava is a biotechnology ...

EST Cassava Sciences (SAVA) sinks 84% to $4.21 after Alzheimer’s study missDon't Miss our Black Friday Offers:Unlock your investing ...

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Billionaire Ken ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...